Chidamide plus decitabine synergistically induces apoptosis of acute myeloid leukemia cells by upregulating
Chidamide
PERP
acute myeloid leukemia
apoptosis
decitabine
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
03
2020
accepted:
15
06
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Acute myeloid leukemia (AML) is a malignant clonal disease that originates from hematopoietic stem cells. Because AML has a generally unsatisfactory long-term prognosis, new therapeutic options are required. To this end, we explored the effects of chidamide and decitabine alone or in combination on the AML cell lines THP-1, MV4-11, HL60, and Kasumi-1. Notably, the two drugs exhibited a synergistic effect against these cell lines. Similarly, we also found potential synergistic effects in primary cells of relapsed/refractory (r/r) AML. A transcriptome sequencing analysis performed to elucidate the underlying molecular mechanism revealed differentially expressed genes and regulatory pathways, particularly with regard to apoptosis, when comparing cells subjected to single and combination treatments. We identified
Types de publication
Journal Article
Langues
eng
Pagination
3461-3475Informations de copyright
AJTR Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Haematologica. 2018 Aug;103(8):1369-1379
pubmed: 29773595
Blood. 2016 Jul 28;128(4):488-96
pubmed: 27235136
Blood Cancer J. 2016 Jul 01;6(7):e441
pubmed: 27367478
Nature. 2017 Jul 6;547(7661):104-108
pubmed: 28658204
Lancet. 2018 Aug 18;392(10147):593-606
pubmed: 30078459
Biochem Biophys Res Commun. 2010 Feb 5;392(2):190-5
pubmed: 20060381
Nat Rev Cancer. 2010 Oct;10(10):721-8
pubmed: 20844554
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Intractable Rare Dis Res. 2016 Aug;5(3):185-91
pubmed: 27672541
Br J Haematol. 2018 Feb;180(4):484-500
pubmed: 29193012
Ann Oncol. 2015 Aug;26(8):1766-71
pubmed: 26105599
Recent Results Cancer Res. 2014;201:269-97
pubmed: 24756800
Leukemia. 2019 Dec;33(12):2795-2804
pubmed: 31628431
Blood. 2014 Feb 27;123(9):1341-52
pubmed: 24415537
N Am J Med Sci. 2012 Sep;4(9):429-34
pubmed: 23050259
Leukemia. 2014 Nov;28(11):2155-64
pubmed: 24699304
Leukemia. 2019 Apr;33(4):945-956
pubmed: 30470836
Genes Dev. 2000 Mar 15;14(6):704-18
pubmed: 10733530
Blood Adv. 2019 Feb 26;3(4):508-518
pubmed: 30760466
Cell. 2005 Mar 25;120(6):843-56
pubmed: 15797384
Br J Cancer. 2016 Oct 11;115(8):983-992
pubmed: 27584665
Phytomedicine. 2019 Mar 15;56:94-102
pubmed: 30668358
Cancer Res. 1995 Nov 15;55(22):5276-82
pubmed: 7585588
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Stem Cell Res Ther. 2019 Aug 19;10(1):259
pubmed: 31426846
Leukemia. 2015 Jun;29(6):1267-78
pubmed: 25482131
Cancer Immunol Immunother. 2015 Oct;64(10):1251-60
pubmed: 26105625
Blood. 2010 Oct 28;116(17):3147-56
pubmed: 20558611
J Clin Pharm Ther. 2017 Dec;42(6):786-789
pubmed: 28646565
Blood. 2009 Sep 17;114(12):2489-96
pubmed: 19528532
Blood. 2019 Feb 14;133(7):730-742
pubmed: 30552097
Oncogene. 2016 Nov 3;35(44):5759-5769
pubmed: 27109096
Curr Biol. 2003 Nov 11;13(22):1985-90
pubmed: 14614825